Question 1

What is combined oxidative phosphorylation defect type 25?

Accepted Answer

Combined oxidative phosphorylation defect type 25 is a condition in which the body’s ability to produce energy is impaired due to a mutation in the MARS2 gene. This disorder affects multiple organ systems, with prominent involvement of the nervous system and features that impact facial structure, muscle tone, and growth. It is inherited in an autosomal recessive pattern, meaning that affected individuals receive a mutated copy of the gene from each parent. The condition is extremely rare, affecting fewer than 1 in 1,000,000 people.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 25?

Accepted Answer

Individuals with combined oxidative phosphorylation defect type 25 typically exhibit a constellation of features that impact several body systems. Characteristic findings include facial dysmorphisms such as anteverted nares, a short nose, depressed nasal bridge, low-set ears, and a long philtrum. Neurologically, affected children experience global developmental delay and, along with generalized hypotonia, may show signs of cerebellar atrophy. Additionally, many individuals present with feeding difficulties, reduced circulating growth hormone concentration, and respiratory complications such as aspiration pneumonia. Other features that occur in a subset of patients include smooth philtrum, hypoplasia of the pons, failure to thrive, wide nasal bridge, prominent forehead, chronic constipation, hypertelorism, ventriculomegaly, cerebral atrophy, intraventricular hemorrhage, and syndactyly. Not all individuals experience all these features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation defect type 25?

Accepted Answer

The condition is caused by a mutation in the MARS2 gene, which plays a crucial role in mitochondrial function and energy production. It is inherited in an autosomal recessive manner, meaning that both parents must carry a copy of the mutated gene for a child to be affected. This inheritance pattern means that each sibling of an affected individual has a 25% chance of being affected. The condition is particularly more common in families where parents share a common ancestor, as this increases the likelihood of both carrying the same rare genetic variant. Genetic counseling is recommended for families to better understand the risks and implications for future pregnancies. Associated genes include MARS2.

Question 4

How is combined oxidative phosphorylation defect type 25 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 25 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 25?

Accepted Answer

combined oxidative phosphorylation defect type 25 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 25 diagnosed?

Accepted Answer

Diagnosis of combined oxidative phosphorylation defect type 25 is established through molecular genetic testing, which identifies pathogenic variants in the MARS2 gene. Clinical evaluation, including a careful assessment of characteristic physical findings such as facial dysmorphisms and global developmental delay, supports the decision to pursue genetic testing. Because the symptoms of this condition can overlap with those of other disorders, genetic confirmation is essential for an accurate diagnosis.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 25?

Accepted Answer

Currently, management focuses on supportive care and symptom management, with treatment plans tailored to the individual’s needs. Because no treatments have been specifically approved for combined oxidative phosphorylation defect type 25, care typically involves a multidisciplinary team that may include specialists in neurology, nutrition, respiratory therapy, and developmental pediatrics. Regular surveillance is an essential part of long-term care, helping to identify potential complications early. Genetic counseling is also recommended so that families can explore reproductive options and receive guidance on managing the condition.

Question 8

What are the potential complications of combined oxidative phosphorylation defect type 25?

Accepted Answer

Individuals with combined oxidative phosphorylation defect type 25 may face various complications due to the involvement of multiple organ systems. Common issues include feeding difficulties, respiratory problems like aspiration pneumonia, and growth challenges due to reduced growth hormone levels. Regular monitoring is important to catch these complications early and manage them effectively.

Question 9

How does combined oxidative phosphorylation defect type 25 affect daily life for patients and families?

Accepted Answer

Living with combined oxidative phosphorylation defect type 25 can be challenging for both patients and their families. Daily life may involve managing feeding difficulties, ensuring proper nutrition, and addressing developmental delays. Families often need to coordinate care with a team of specialists, which can require significant time and effort.

Question 10

What is the prognosis for individuals with combined oxidative phosphorylation defect type 25?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation defect type 25 can vary widely. Some may experience periods of stabilization, while others may face ongoing challenges related to feeding, growth, and respiratory function. Access to specialized care and regular monitoring can improve outcomes and help families manage the condition more effectively.

Question 11

What specialists should families consult for managing combined oxidative phosphorylation defect type 25?

Accepted Answer

Families managing combined oxidative phosphorylation defect type 25 should consult a multidisciplinary team of specialists. This may include neurologists, nutritionists, respiratory therapists, and developmental pediatricians. Working with these experts can help ensure that all aspects of the condition are addressed and that the patient receives comprehensive care.

Kisho

combined oxidative phosphorylation defect type 25

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

combined oxidative phosphorylation defect type 25

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 25?

What are the symptoms of combined oxidative phosphorylation defect type 25?

What causes combined oxidative phosphorylation defect type 25?

How is combined oxidative phosphorylation defect type 25 inherited?

How rare is combined oxidative phosphorylation defect type 25?

How is combined oxidative phosphorylation defect type 25 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 25?

What are the potential complications of combined oxidative phosphorylation defect type 25?

How does combined oxidative phosphorylation defect type 25 affect daily life for patients and families?

What is the prognosis for individuals with combined oxidative phosphorylation defect type 25?

What specialists should families consult for managing combined oxidative phosphorylation defect type 25?

Explore clinical features